SG10201501050RA - Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof - Google Patents
Secondary Structure Stabilized NMDA Receptor Modulators And Uses ThereofInfo
- Publication number
- SG10201501050RA SG10201501050RA SG10201501050RA SG10201501050RA SG10201501050RA SG 10201501050R A SG10201501050R A SG 10201501050RA SG 10201501050R A SG10201501050R A SG 10201501050RA SG 10201501050R A SG10201501050R A SG 10201501050RA SG 10201501050R A SG10201501050R A SG 10201501050RA
- Authority
- SG
- Singapore
- Prior art keywords
- secondary structure
- nmda receptor
- receptor modulators
- structure stabilized
- stabilized
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30347210P | 2010-02-11 | 2010-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201501050RA true SG10201501050RA (en) | 2015-04-29 |
Family
ID=44368160
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012059358A SG183265A1 (en) | 2010-02-11 | 2011-02-11 | Secondary structure stabilized nmda receptor modulators and uses thereof |
| SG10201501050RA SG10201501050RA (en) | 2010-02-11 | 2011-02-11 | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
| SG10201811584RA SG10201811584RA (en) | 2010-02-11 | 2011-02-11 | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012059358A SG183265A1 (en) | 2010-02-11 | 2011-02-11 | Secondary structure stabilized nmda receptor modulators and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201811584RA SG10201811584RA (en) | 2010-02-11 | 2011-02-11 | Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9101612B2 (enExample) |
| EP (1) | EP2542254B1 (enExample) |
| JP (4) | JP5928828B2 (enExample) |
| CN (2) | CN105037492A (enExample) |
| AU (1) | AU2011215704B2 (enExample) |
| BR (1) | BR112012020142A2 (enExample) |
| CA (1) | CA2789331C (enExample) |
| ES (1) | ES2706063T3 (enExample) |
| IL (1) | IL221400A (enExample) |
| MX (1) | MX2012009388A (enExample) |
| RU (1) | RU2566821C2 (enExample) |
| SG (3) | SG183265A1 (enExample) |
| WO (1) | WO2011100585A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2331571B1 (en) | 2008-09-18 | 2015-08-26 | Northwestern University | Nmda receptor modulators and uses thereof |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| RU2566821C2 (ru) | 2010-02-11 | 2015-10-27 | Нортвестерн Юниверсити | Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение |
| CN105408336B (zh) * | 2013-01-29 | 2018-06-26 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| AU2014212487C1 (en) * | 2013-01-29 | 2018-10-25 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| BR112015018095A2 (pt) * | 2013-01-29 | 2017-07-18 | Naurex Inc | moduladores de receptor nmda de espiro-lactama e usos dos mesmos |
| WO2014120783A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| ES2618421T3 (es) | 2013-01-29 | 2017-06-21 | Aptinyx Inc. | Moduladores espiro-lactama del receptor NMDA y usos de los mismos |
| MX378668B (es) * | 2013-10-28 | 2025-03-10 | Naurex Inc | Profarmacos y moduladores de receptores nmda, sales y usos de estos. |
| EP3134103B1 (en) * | 2014-04-25 | 2020-01-15 | Naurex Inc. | Stable compositions of neuroactive peptides |
| JP6688748B2 (ja) * | 2014-06-23 | 2020-04-28 | ノースウェスタン ユニバーシティ | 片頭痛の治療または改善方法 |
| JP2017525684A (ja) * | 2014-07-24 | 2017-09-07 | ノーレックス インコーポレイテッド | Ｎ−メチル−ｄ−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法 |
| ES2818254T3 (es) | 2015-10-14 | 2021-04-09 | Bristol Myers Squibb Co | Antagonistas selectivos de NR2B |
| ES2822830T3 (es) * | 2015-10-14 | 2021-05-05 | Bristol Myers Squibb Co | Antagonistas selectivos de NR2B |
| EP3362080A1 (en) * | 2015-10-16 | 2018-08-22 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
| WO2017136348A1 (en) * | 2016-02-01 | 2017-08-10 | Naurex, Inc. | Processes for synthesis of dipyrrolidine peptide compounds |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2017267708B2 (en) | 2016-05-19 | 2020-02-20 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| EA201990424A1 (ru) | 2016-08-01 | 2019-08-30 | Аптиникс Инк. | Спиролактамовые модуляторы nmda-рецептора и их применение |
| ES2972533T3 (es) | 2016-08-01 | 2024-06-13 | Tenacia Biotechnology Hong Kong Co Ltd | Moduladores del receptor de NMDA a base de espirolactama, y sus usos |
| AU2017306158B2 (en) | 2016-08-01 | 2021-10-14 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
| WO2018026798A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| ES2973283T3 (es) | 2016-08-01 | 2024-06-19 | Tenacia Biotechnology Hong Kong Co Ltd | Moduladores de receptores de NMDA espirolactámicos y usos de los mismos |
| SG11202007251XA (en) * | 2018-01-31 | 2020-08-28 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102761196B1 (ko) | 2018-01-31 | 2025-02-03 | 테나시아 바이오테크놀로지 (홍콩) 코., 리미티드 | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| CN113480596A (zh) * | 2019-04-09 | 2021-10-08 | 北京广为医药科技有限公司 | 一种调节nmda受体活性的化合物、其药物组合物及用途 |
| CN114599354A (zh) * | 2019-08-01 | 2022-06-07 | 阿普廷伊克斯股份有限公司 | 与nmda受体相互作用的抗体的水平升高相关性障碍的治疗方法 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| CN114957444B (zh) * | 2022-05-31 | 2023-09-19 | 陕西脉元生物科技有限公司 | 一种nmdar的nr1亚基缺失突变体、突变体细胞及构建方法和应用 |
| CN114957445B (zh) * | 2022-05-31 | 2023-09-19 | 陕西脉元生物科技有限公司 | 一种nmdar nr1亚基、nmdar的突变体及其构建方法和应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683221A (en) | 1986-01-09 | 1987-07-28 | Scripps Clinic And Research Foundation | Lymphocyte-activating polypeptides |
| CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
| US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| CA2058975C (en) | 1990-10-30 | 2000-06-06 | Shuichi Kasai | Antiinflammatory gel preparation |
| JP3318622B2 (ja) | 1992-05-27 | 2002-08-26 | 独立行政法人産業技術総合研究所 | プロリルエンドペプチダーゼ阻害剤 |
| FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
| SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
| US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| NZ332347A (en) | 1996-06-07 | 2000-05-26 | Zeneca Ltd | Peptide derivatives containing a hydrophobic group, L-amino acid residues and modified L-amino acid residues |
| WO1998005782A1 (en) | 1996-08-02 | 1998-02-12 | Zymogenetics, Inc. | Testis-specific insulin homolog polypeptides |
| US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
| US6897028B1 (en) | 1997-07-07 | 2005-05-24 | Florida State University | Identification of molecular targets |
| WO1999002733A1 (en) | 1997-07-07 | 1999-01-21 | Florida State University | Identification of molecular targets |
| WO1999024584A1 (en) | 1997-11-12 | 1999-05-20 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
| US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
| US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
| US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
| US6902886B1 (en) | 1998-11-06 | 2005-06-07 | The Research Foundation Of State University Of New York | Genetic assay for protein nuclear transport |
| AU1724000A (en) | 1998-11-12 | 2000-05-29 | Nyxis, Inc. | Diagnostic assay for cancer |
| US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| WO2001036685A2 (en) | 1999-11-17 | 2001-05-25 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
| US6521414B2 (en) | 2000-02-01 | 2003-02-18 | Agy Therapeutics, Inc. | Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1 |
| WO2001096606A2 (en) | 2000-06-14 | 2001-12-20 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
| WO2001098367A2 (en) | 2000-06-22 | 2001-12-27 | Nyxis Neurotherapies, Inc. | Neuroactive peptides for treatment of hypoxia and related conditions |
| IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
| US20020142287A1 (en) | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
| AU2002248553A1 (en) | 2001-03-07 | 2002-09-24 | Cognetix, Inc | Linear y-carboxyglutamate rich conotoxins |
| WO2002072609A2 (en) | 2001-03-12 | 2002-09-19 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
| US7863304B2 (en) | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| CA2449168A1 (en) | 2001-05-31 | 2002-12-05 | The Trustees Of Princeton University | Iap binding peptides and assays for identifying compounds that bind iap |
| WO2003010540A1 (en) | 2001-07-25 | 2003-02-06 | Nyxis Neurotherapies, Inc. | Method of identifying nmda-related agent |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| CA2534909A1 (en) | 2003-08-08 | 2005-02-17 | The Burnham Institute | P16 mediated regulation of nmda receptors |
| US7662856B2 (en) | 2003-08-29 | 2010-02-16 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| AU2006282942B2 (en) * | 2005-08-26 | 2012-07-26 | Wisconsin Alumni Research Foundation | Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same |
| WO2007027559A2 (en) * | 2005-08-29 | 2007-03-08 | Shashoua Victor E | Neuroprotective and neurorestorative methods and compositions |
| WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| JP2010503677A (ja) | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 脂質代謝の障害を治療するためのアゼチジノン誘導体 |
| CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
| CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
| WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
| AU2009278075B2 (en) | 2008-08-07 | 2013-07-04 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
| EP2331571B1 (en) | 2008-09-18 | 2015-08-26 | Northwestern University | Nmda receptor modulators and uses thereof |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| TW201028171A (en) | 2008-12-15 | 2010-08-01 | Calpis Co Ltd | Peptides for inhibiting skin aging |
| WO2011003064A2 (en) | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| HRP20140784T1 (hr) | 2009-10-05 | 2014-10-10 | Northwestern University | Glyx-13 za uporabu u postupku tretiranja refraktornih depresija |
| EP2512243B1 (en) * | 2009-12-17 | 2016-04-06 | Merck Sharp & Dohme Corp. | Quinoline amide m1 receptor positive allosteric modulators |
| RU2566821C2 (ru) | 2010-02-11 | 2015-10-27 | Нортвестерн Юниверсити | Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| BR112013027554A2 (pt) | 2011-04-27 | 2016-09-06 | Univ Northwestern | "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios" |
| US8795919B2 (en) | 2011-11-29 | 2014-08-05 | Societe BIC & Sanyo Electric Co., Ltd. | Fuel cell layer |
-
2011
- 2011-02-11 RU RU2012138710/04A patent/RU2566821C2/ru active
- 2011-02-11 AU AU2011215704A patent/AU2011215704B2/en active Active
- 2011-02-11 SG SG2012059358A patent/SG183265A1/en unknown
- 2011-02-11 MX MX2012009388A patent/MX2012009388A/es active IP Right Grant
- 2011-02-11 US US13/578,189 patent/US9101612B2/en active Active
- 2011-02-11 CN CN201510222007.2A patent/CN105037492A/zh active Pending
- 2011-02-11 CA CA2789331A patent/CA2789331C/en active Active
- 2011-02-11 ES ES11761468T patent/ES2706063T3/es active Active
- 2011-02-11 WO PCT/US2011/024583 patent/WO2011100585A1/en not_active Ceased
- 2011-02-11 SG SG10201501050RA patent/SG10201501050RA/en unknown
- 2011-02-11 SG SG10201811584RA patent/SG10201811584RA/en unknown
- 2011-02-11 BR BR112012020142-5A patent/BR112012020142A2/pt not_active Application Discontinuation
- 2011-02-11 JP JP2012553046A patent/JP5928828B2/ja active Active
- 2011-02-11 EP EP11761468.5A patent/EP2542254B1/en active Active
- 2011-02-11 CN CN2011800146633A patent/CN102933226A/zh active Pending
-
2012
- 2012-08-09 IL IL221400A patent/IL221400A/en active IP Right Grant
-
2015
- 2015-05-14 US US14/712,481 patent/US9593145B2/en active Active
-
2016
- 2016-04-13 JP JP2016080043A patent/JP6328169B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-17 JP JP2018079295A patent/JP2018119004A/ja not_active Withdrawn
-
2020
- 2020-03-17 JP JP2020046041A patent/JP2020117510A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102933226A (zh) | 2013-02-13 |
| EP2542254A1 (en) | 2013-01-09 |
| IL221400A (en) | 2016-07-31 |
| JP2018119004A (ja) | 2018-08-02 |
| SG10201811584RA (en) | 2019-01-30 |
| JP2013519683A (ja) | 2013-05-30 |
| RU2012138710A (ru) | 2014-03-20 |
| MX2012009388A (es) | 2012-10-01 |
| CA2789331A1 (en) | 2011-08-18 |
| IL221400A0 (en) | 2012-10-31 |
| JP2016185948A (ja) | 2016-10-27 |
| US20160115197A1 (en) | 2016-04-28 |
| US20130053325A1 (en) | 2013-02-28 |
| SG183265A1 (en) | 2012-09-27 |
| US9593145B2 (en) | 2017-03-14 |
| JP5928828B2 (ja) | 2016-06-01 |
| AU2011215704A1 (en) | 2012-08-30 |
| BR112012020142A2 (pt) | 2020-08-18 |
| CN105037492A (zh) | 2015-11-11 |
| ES2706063T3 (es) | 2019-03-27 |
| EP2542254B1 (en) | 2018-09-26 |
| JP2020117510A (ja) | 2020-08-06 |
| CA2789331C (en) | 2017-11-07 |
| EP2542254A4 (en) | 2013-07-10 |
| RU2566821C2 (ru) | 2015-10-27 |
| AU2011215704B2 (en) | 2015-07-23 |
| US9101612B2 (en) | 2015-08-11 |
| WO2011100585A1 (en) | 2011-08-18 |
| JP6328169B2 (ja) | 2018-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL221400A0 (en) | Secondary structure stabilized nmda receptor modulators and uses thereof | |
| GB2483736B (en) | Estrogen receptor modulators and uses thereof | |
| HRP20180848T1 (hr) | Modulatori androgenih receptora i njihove upotrebe | |
| SG11201401776WA (en) | Nmda receptor modulators and uses thereof | |
| ZA201208603B (en) | Estrogen receptor modulators and uses thereof | |
| EP2791132A4 (en) | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
| IL234487A0 (en) | Estrogen receptor modulators and their uses | |
| EP2927224B8 (en) | Receptor antagonists | |
| IL211802A0 (en) | Nmda receptor modulators and uses thereof | |
| GB201004739D0 (en) | Receptor modulators | |
| ZA201400406B (en) | Trans-clomiphene metabolites and uses thereof | |
| ZA201303950B (en) | Glucagon receptor modulators | |
| IL238629A0 (en) | Antibodies against prokinectin receptor and their uses | |
| HK1185066A (en) | Estrogen receptor modulators and uses thereof | |
| HK1179972A (en) | Androgen receptor modulators and uses thereof | |
| HK1176233A (en) | Nuclear receptor binding agents | |
| HK1193719A (zh) | 核激素受體調節劑 |